Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals

Endocrine Reviews

Volumn 34, Issue 3, 2013, Pages 377-412

  Moon, Hyun Seuk ^a   Dalamaga, Maria ^b   Kim, Sang Yong ^a,c   Polyzos, Stergios A ^d   Hamnvik, Ole Petter ^a,e   Magkos, Faidon ^a   Paruthi, Jason ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c Chosun University College of Medicine   (South Korea)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENYLATE KINASE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; RESISTIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA;

ALTERNATIVE RNA SPLICING; ANTIDIABETIC ACTIVITY; APOPTOSIS; AUTOPHOSPHORYLATION; BODY MASS; CD4+ T LYMPHOCYTE; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; ENERGY BALANCE; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; FRAMESHIFT MUTATION; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; IMMUNOMODULATION; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LEPTIN DEFICIENCY; LIPODYSTROPHY; LIPOTOXICITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STEATOSIS; SUBCUTANEOUS FAT;

ANIMALS; DIABETES MELLITUS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; LIPODYSTROPHY, CONGENITAL GENERALIZED; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION;

EID: 84878656502     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1053     Document Type: Review

References (321)

1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
2. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-543.
3. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol. 2010;31:377-393.
4. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet. 2005;366:74-85.
5. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543-546.
6. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546-549.
7. Chan JL, Moschos SJ, Bullen J, et al. Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-α receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab. 2005;90:1625-1631.
8. Houseknecht KL, Mantzoros CS, Kuliawat R, Hadro E, Flier JS, Kahn BB. Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes. 1996;45:1638-1643.
9. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes. 2002;51:1337-1345.
10. Blüher S, Mantzoros CS. Leptin in humans: lessons from translational research.AmJ Clin Nutr. 2009;89:991S-997S.
11. Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology: emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2:318-327.
12. Brinkoetter M, Magkos F, Vamvini M, Mantzoros CS. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. Am J Physiol Endocrinol Metab. 2011;301:E99-E104.
13. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152:93-100.
14. Bluher S, Mantzoros CS. The role of leptin in regulating neuroendocrine function in humans. J Nutr. 2004;134: 2469S-2474S.
15. ChanJL, Bluher S, Yiannakouris N, SuchardMA,Kratzsch J, Mantzoros CS. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes. 2002;51:2105-2112.
16. Chan JL, Mantzoros CS. Leptin and the hypothalamicpituitary regulation of the gonadotropin-gonadal axis. Pituitary. 2001;4:87-92.
17. Mantzoros CS. Role of leptin in reproduction. Ann N Y Acad Sci. 2000;900:174-183.
18. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999;130:671-680.
19. Moon HS, Chamberland JP, Mantzoros CS. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C(2)C (12) muscle and AML12 liver cell lines. Diabetologia. 2012;55: 215-225.
20. Moon HS, Matarese G, Brennan AM, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes. 2011;60:1647-1656.
21. MoonHS, Chamberland JP, Diakopoulos KN, et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care. 2011;34:132-138.
22. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999; 282:1568-1575.
23. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295.
24. de Luis DA, Perez Castrillón JL, Dueñas A. Leptin and obesity. Minerva Medica. 2009;100:229-236.
25. Leibel RL. Molecular physiology of weight regulation in mice and humans. Int J Obes (Lond). 2008;32:S98-S108.
26. Minocci A, Savia G, Lucantoni R, et al. A Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord. 2000;24: 1139.
27. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53: 319-336.
28. Müller TD, Föcker M, Holtkamp K, Herpertz-Dahlmann B, Hebebrand J. Leptin-mediated neuroendocrine alterations in anorexia nervosa: somatic and behavioral implications. Child Adolesc Psychiatr Clin NorthAm. 2009;18: 117-129.
29. Leshan RL, Björnholm M, Münzberg H, Myers MG Jr. 2006 Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring). 14:208S-212S.
30. Zhang Y, Scarpace PJ. The role of leptin in leptin resistance and obesity. Physiol Behav. 2006;88:249-256.
31. Peelman F, Couturier C, Dam J, Zabeau L, Tavernier J, Jockers R. Techniques: new pharmacological perspectives for the leptin receptor. Trends Pharmacol Sci. 2006;27: 218-225.
32. Walker CD, Naef L, d'Asti E, et al. Perinatal maternal fat intake affects metabolism and hippocampal function in the offspring: a potential role for leptin. Ann N Y Acad Sci. 2008;1144:189-202.
33. Cohen MM Jr. 2006 Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling.AmJ Med Genet A. 140:515-524.
34. Frühbeck G. 2006 Intracellular signalling pathways activated by leptin. Biochem J. 393(Pt 1):7-20.
35. Lappas M, Yee K, Permezel M, Rice GE. Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol. 2005;186: 457-465.
36. Mencarelli A, Distrutti E, Renga B, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6:e229-e278.
37. Lee Y, Yu X, Gonzales F, et al. PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A. 2002;99:11848-11853.
38. Papathanassoglou E, El-Haschimi K, Li XC, Matarese G, Strom T, Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol. 2006;176:7745-7752.
39. Muhlhausler BS, Morrison JL, McMillen IC. Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-γ target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation. Endocrinology. 2009;150:4287-4294.
40. Prieur X, Tung YC, Griffin JL, Farooqi IS, O'Rahilly S, Coll AP. Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology. 2008;149:5432-5439.
41. Coya R, Martul P, Algorta J, Aniel-Quiroga MA, Busturia MA, Señarís R. Progesterone and human placental lactogen inhibit leptin secretion on cultured trophoblast cells from humanplacentas at term. Gynecol Endocrinol. 2005;21:27-32.
42. Seufert J. Leptin effects on pancreatic β-cell gene expression and function. Diabetes. 2004;53 Suppl 1:S152-S158.
43. Gallardo N, Bonzón-Kulichenko E, Fernández-Agulló T, et al. Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology. 2007;148:5604-5610.
44. Sakoguchi T, Horiuchi M, Asakawa A, Ushikai M, Yoshida G, Fujimiya M, Kato I, Nakazato M, Takeuchi T, Saheki T, Inui A. Failure of the feeding response to fasting in carnitine-deficient juvenile visceral steatosis (JVS) mice: involvement of defective acyl-ghrelin secretion and enhanced corticotropin-releasing factor signaling in the hypothalamus. Biochim Biophys Acta. 2009;1792:1087-1093.
45. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipids Res. 2010;51:771-784.
46. Uotani S, Bjørbaek C, Tornøe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes. 1999;48:279-286.
47. Lee Y, Hirose H, Ohneda M, Johnson J, McGarry JD, Unger RH. β-Cell lipotoxicity in the pathogenesis of noninsulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci U S A. 1994;91:10878-10882.
48. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 2001; 15:312-321.
49. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A. 1999;96:2327-2332.
50. Koyama K, Chen G, Lee Y, Unger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol Endocrinol Metab. 1997;273:E708-E713.
51. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acidinduced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A. 1998;95:2498-2502.
52. Shimabukuro M, Wang MY, Zhou YT, Newgard CB, UngerRH. Protection against lipoapoptosis ofβ-cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A. 1998;95:9558-9561.
53. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores β cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273:3547-3550.
54. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010;1801:209-214.
55. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010;21:345-352.
56. Unger R, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985;28:119-121.
57. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol. 2009;46:113-118.
58. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A. 2010;107:4813-4819.
59. Gray SL, Donald C, Jetha A, Covey SD, Kieffer TJ. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic β-cell leptin signaling. Endocrinology. 2010; 151:4178-4186.
60. Maedler K, Schulthess FT, Bielman C, et al. Glucose and leptin induce apoptosis in human β-cells and impair glucosestimulated insulin secretion through activation of c-Jun Nterminal kinases. FASEB J. 2008;22:1905-1913.
61. do Prado WL, de Piano A, Lazaretti-Castro M, et al. Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolescents. J Bone Miner Metab. 2009;27:613-619.
62. Miras M, Ochetti M, Martín S, et al. Serum levels of adiponectin and leptin in children born small for gestational age: relation to insulin sensitivity parameters. J Pediatr Endocrinol Metab. 2010;23:463-471.
63. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005;41:753-760.
64. Berglund ED, Vianna CR, Donato J Jr, et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest. 2012; 122:1000.
65. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov. 2012;11:692-708.
66. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A. 2010; 107:16009-16012.
67. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A. 2008;105:14070-14075.
68. Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A. 2010;107:17391-17396.
69. Kalra SP. Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. Peptides. 2009;30:1957-1963.
70. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4-12.
71. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol. 2005;15;174:3137-3142.
72. Carbone F,LARocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie. 2012;94:2082-2088.
73. TanakaM,Suganami T, Kim-SaijoM,et al. Role of central leptin signaling in the starvation-induced alteration of Bcell development. J Neurosci. 2011;31:8373-8380.
74. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897-900.
75. Tian Z, Sun R, Wei H, Gao B. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun. 2002;298:297-302.
76. De Rosa V, Procaccini C, Calì G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007;26:241-255.
77. Mancuso P, Gottschalk A, Phare SM, Peters-Golden M, Lukacs NW, Huffnagle GB. Leptin-deficient mice exhibit impaired host defense in Gram-negative pneumonia. J Immunol. 2002;168:4018-4024.
78. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999;84:3686-3695.
79. Smith AG, Sheridan PA, Harp JB, Beck MA. Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr. 2007; 137:1236-1243.
80. McCormack D, Schneider J, McDonald D, McFadden D. The antiproliferative effects of pterostilbene on breast cancer in vitro are via inhibition of constitutive and leptininduced Janus kinase/signal transducer and activator of transcription activation. Am J Surg. 2011;202:541-544.
81. Feng Y, Shao R, Weijdegård B, et al. Effects of androgen and leptin on behavioral and cellular responses in female rats. Horm Behav. 2011;60:427-438.
82. Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol. 2011;17:3922-3932.
83. Okitsu K, Kanda T, Imazeki F, et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer. 2010;1:859-867.
84. Zhang H, Zhang D, Luan X, Xie G, Pan X. Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells. J Int Med Res. 2010;38:1673-1681.
85. Saito M, Nagasawa M, Takada H, et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med. 2011;208:235-249.
86. Heimall J, Davis J, Shaw PA, et al. Paucity of genotypephenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES). Clin Immunol. 2011;139:75-84.
87. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med. 2008;14:667-675.
88. Gao Q, Wolfgang MJ, Neschen S, et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci U S A. 2004;101:4661-4666.
89. Dzamko N, van Denderen BJ, Hevener AL, et al.AMPKβ1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J Biol Chem. 2010;285:115-122.
90. Dzamko NL, Steinberg GR. AMPK-dependent hormonal regulation of whole-body energy metabolism. Acta Physiol (Oxf). 2009;196:115-127.
91. 1-AMPactivated protein kinase-α1 in high-fat fed rats. J Pharm Pharmacol. 2009;61:1339-1346.
92. Kohan AB, Talukdar I, Walsh CM, Salati LM. A role for AMPK in the inhibition of glucose-6-phosphate dehydrogenase by polyunsaturated fatty acids. Biochem Biophys Res Commun. 2009;388:117-121.
93. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44:87-97.
94. Suzuki A,OkamotoS, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor α gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the α2 form of AMP-activated protein kinase. Mol Cell Biol. 2007;27:4317-4327.
95. Kus V, Prazak T, Brauner P, et al. Induction of muscle thermogenesis by high-fat diet in mice: association with obesity-resistance. Am J Physiol Endocrinol Metab. 2008; 295:E356-E367.
96. Tanaka T, Masuzaki H, Yasue S, et al. Central melanocortin signaling restores skeletal muscle AMP-activated protein kinase phosphorylation in mice fed a high-fat diet. Cell Metab. 2007;5:395-402.
97. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB. Insulin resistance due to nutrient excess: Is it a consequence of AMPK downregulation? Cell Cycle. 2011;10:3447-3451.
98. Grisouard J, Dembinski K, Mayer D, Keller U, Müller B, Christ-Crain M. Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation. Diabetol Metab Syndr. 2011;3:16.
99. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339-343.
100. Nascimento AF, Luvizotto RA, Leopoldo AS, et al. Longterm high-fat diet-induced obesity decreases the cardiac leptin receptor without apparent lipotoxicity. Life Sci. 2011;88:1031-1038.
101. GunnRM,HailesHC.Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. J Chem Biol. 2008;1:49-62.
102. Cho JE, Kim YS, Park S, Cho SN, Lee H. Mycobacterium tuberculosis-induced expression of leukotactin-1 is mediated by the PI3-K/PDK1/Akt signaling pathway. Mol Cells. 2010;29:35-39.
103. Zhang Z, Song T, Jin Y, et al. Epidermal growth factor receptor regulates MT1-MMP and MMP-2 synthesis in SiHa cells via both PI3-K/AKT andMAPK/ERKpathways. Int J Gynecol Cancer. 2009;19:998-1003.
104. Filiputti E, Rafacho A, Araújo EP, et al. Augmentation of insulin secretion by leucine supplementation in malnourished rats: possible involvement of the phosphatidylinositol 3-phosphate kinase/mammalian target protein of rapamycin pathway. Metab Clin Exp. 2010;59:635-644.
105. Cui W, Li W, Han R, et al. PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP(β)-induced neuronal apoptosis. Neurochem Int. 2011;59:945-953.
106. Que J, Lian Q, El Oakley RM, Lim B, Lim SK. PI3 K/Akt/mTOR-mediated translational control regulates proliferation and differentiation of lineage-restricted RoSH stem cell lines. J Mol Signal. 2007;2:9.
107. Wang Y, Yan W, Lu X, et al. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the av?3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol. 2011;90:642-648.
108. Rodríguez A, Gómez-Ambrosi J, Catalán V, Fortuño A, Frühbeck G. Leptin inhibits the proliferation of vascular smooth muscle cells induced by angiotensin II through nitric oxide-dependent mechanisms. Mediators Inflamm. 2010;1054-1089.
109. Rodríguez A, Catalán V, Gómez-Ambrosi J, et al. Insulinand leptin-mediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade. J Clin Endocrinol Metab. 2011;96:E586-E597.
110. Cheng SP, Yin PH, Hsu YC, et al. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep. 2011;26:1265-1271.
111. Samuel-Mendelsohn S, Inbar M, Weiss-Messer E, Niv-Spector L, Gertler A, Barkey RJ. Leptin signaling and apoptotic effects inhumanprostate cancer cell lines. Prostate. 2011;71:929-945.
112. Barazzoni R, Zanetti M, Bosutti A, et al. Moderate caloric restriction, but not physiological hyperleptinemia per se, enhances mitochondrial oxidative capacity in rat liver and skeletal muscle-tissue-specific impact on tissue triglyceride content and AKT activation. Endocrinology. 2005;146:2098-2106.
113. Fang X, Fetros J, Dadson KE, Xu A, Sweeney G. Leptin prevents the metabolic effects of adiponectin in L6 myotubes. Diabetologia. 2009;52:2190-2200.
114. Ernst MB, Wunderlich CM, Hess S, et al. Enhanced Stat3 activation in POMC neurons provokes negative feedback inhibition of leptin and insulin signaling in obesity. J Neurosci. 2009;29:11582-11593.
115. Shetty GK, Matarese G, Magkos F, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011;165:249-254.
116. Mirshamsi S, Laidlaw HA, Ning K, et al. Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PI3K dependent actin reorganization and KATP channel activation. BMC Neurosci. 2004;5:54.
117. Hill JW, Elias CF, FukudaM,et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11:286-297.
118. Al-Qassab H, Smith MA, Irvine EE, et al. Dominant role of the p110β isoform of PI3K over p110α in energy homeostasis regulation byPOMCandAgRPneurons. Cell Metab. 2009;10:343-354.
119. Sasaki T, Kitamura T. Roles of FoxO1 and Sirt1 in the central regulation of food intake. Endocr J. 2010;57:939-946.
120. Wang RH, Kim HS, Xiao C,XuX, Gavrilova O, Deng CX. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011;121:4477-4490.
121. Gu Y, Lindner J, Kumar A, Yuan W, Magnuson MA. Rictor/mTORC2 is essential for maintaining a balance between β-cell proliferation and cell size. Diabetes. 2011;60: 827-837.
122. Cypess AM, Zhang H, Schulz TJ, et al. Insulin/IGF-I regulation of necdin and brown adipocyte differentiation via CREB-and FoxO1-associated pathways. Endocrinology. 2011;152:3680-3689.
123. Coope A, Milanski M, Araújo EP, et al. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus. FEBS Lett. 2008;582: 1471-1476.
124. Reiter CE, Kim JA, Quon MJ. Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: roles for AMP-activated protein kinase, Akt, and FOXO1. Endocrinology. 2010;151:103-114.
125. Iskandar K, Cao Y, Hayashi Y, et al. PDK-1/FoxO1 path-way in POMC neurons regulates Pomc expression and food intake. Am J Physiol Endocrinol Metab. 2010;298: E787-E798.
126. Sasaki T, Kim HJ, Kobayashi M, et al. Induction of hypothalamic Sirt1 leads to cessation of feeding via agouti-related peptide. Endocrinology. 2010;151:2556-2566.
127. Cakir I, Perello M, Lansari O, Messier NJ, Vaslet CA, Nillni EA. Hypothalamic Sirt1 regulates food intake in a rodent model system. PLoS One. 2009;4:e8322.
128. Fernández-Riejos P, Goberna R, Sánchez-Margalet V. Leptin promotes cell survival and activates Jurkat T lymphocytes by stimulation of mitogen-activated protein kinase. Clin Exp Immunol. 2008;151:505-518.
129. Shin EJ, Schram K, Zheng XL, Sweeney G. Leptin attenuates hypoxia/reoxygenation-induced activation of the intrinsic pathway of apoptosis in rat H9c2 cells. J Cell Physiol. 2009;221:490-497.
130. Löthgren A, McCartney M, Rupp Thuresson E, James SR. A model of activation of the protein tyrosine phosphatase SHP-2 by the human leptin receptor. Biochim Biophys Acta. 2001;1545:20-29.
131. Chen W, Garcia JG, Jacobson JR. Integrin β4 attenuates SHP-2 and MAPK signaling and reduces human lung endothelial inflammatory responses. J Cell Biochem. 2010; 110:718-724.
132. Carver KC, Piazza TM, Schuler LA. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J Biol Chem. 2010; 285:8003-8012.
133. Kolli S, Zito CI, Mossink MH, Wiemer EA, Bennett AM. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J Biol Chem. 2004;279:29374-29385.
134. Bjørbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem. 2001;276:4747-4755.
135. Anhê GF, Caperuto LC, Pereira-Da-Silva M, et al. In vivo activation of insulin receptor tyrosine kinase by melatonin in the rat hypothalamus. J Neurochem. 2004;90:559-566.
136. Banno R, Zimmer D, DeJonghe BC, et al. PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. J Clin Invest. 2010;120:720-734.
137. You J,YuY, Jiang L, et al. Signaling through Tyr985 of leptin receptor as an age/diet-dependent switch in the regulation of energy balance. Mol Cell Biol. 2010;30:1650-1659.
138. Chung JH, Choi HJ, Kim SY, et al. Proteomic and biochemical analyses reveal the activation of unfolded protein response, ERK-1/2 and ribosomal protein S6 signaling in experimental autoimmune myocarditis rat model. BMC Genomics. 2011;12:520.
139. Ben-Eliezer M, Phillip M, Gat-Yablonski G. Leptin regulates chondrogenic differentiation in ATDC5 cell-line through JAK/STAT and MAPK pathways. Endocrine. 2007;32:235-244.
140. Katiyar SK, Meeran SM. Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-κB signaling. Free Radic Biol Med. 2007; 42:299-310.
141. Shen J, Sakaida I, Uchida K, Terai S, Okita K. Leptin enhances TNF-α production via p38 and JNKMAPKin LPSstimulated Kupffer cells. Life Sci. 2005;77:1502-1515.
142. Muretta JM, Mastick CC. How insulin regulates glucose transport in adipocytes. Vitam Horm. 2009;80:245-286.
143. Nakayama M. Insulin as a key autoantigen in the development of type 1 diabetes. Diabetes Metab Res Rev. 2011; 27:773-777.
144. Colberg SR. Physical activity, insulin action, and diabetes prevention and control. Curr Diabetes Rev. 2007;3:176-184.
145. Ligon B, Yang J, Morin SB, Ruberti MF, Steer ML. Regulation of pancreatic islet cell survival and replication by γ-aminobutyric acid. Diabetologia. 2007;50:764-773.
146. Wei FY, Suzuki T, Watanabe S, et al. Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. J Clin Invest. 2011;121:3598-3608.
147. Keung W, Palaniyappan A, Lopaschuk GD. Chronic central leptin decreases food intake and improves glucose tolerance in diet-induced obese mice independent of hypothalamic malonyl CoA levels and skeletal muscle insulin sensitivity. Endocrinology. 2011;152:4127-4137.
148. Brøns C, Jacobsen S, Hiscock N, et al. Effects of high-fat overfeeding on mitochondrial function, glucose and fat metabolism, and adipokine levels in low birth weight subjects. Am J Physiol Endocrinol Metab. 2012;302:E43-E51.
149. Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A. 2011;108:15324-15329.
150. Levi J, Gray SL, Speck M, et al. Acute disruption of leptin signaling in vivo leads to increased insulin levels and insulin resistance. Endocrinology. 2011;152:3385-3395.
151. Takahashi A, Shimano H, Nakagawa Y, et al. Transgenic mice overexpressing SREBP-1a under the control of the PEPCK promoter exhibit insulin resistance, but not diabetes. Biochim Biophys Acta. 2005;1740:427-433.
152. Slosberg ED, Desai UJ, Fanelli B, et al. Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein. Diabetes. 2001;50:1813-1820.
153. Kaser S, Föger B, Ebenbichler CF, et al. Influence of leptin and insulin on lipid transfer proteins in human hepatoma cell line, HepG2. Int J Obes Relat Metab Disord. 2001; 25:1633-1639.
154. Maroni P, Bendinelli P, Piccoletti R. Intracellular signal transduction pathways induced by leptin in C2C12 cells. Cell Biol Int. 2005;29:542-550.
155. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci U S A. 2000;97:2355-2360.
156. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011;45:50.
157. Lebrun P, Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol. 2008;192:29-36.
158. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA.Activation ofSOCS-3by resistin.MolCell Biol. 2005; 25:1569-1575.
159. Wang P, Li N, Li JS, LiWQ.The role of endotoxin, TNF-α, and IL-6 in inducing the state of growth hormone insensitivity. World J Gastroenterol. 2002;8:531-536.
160. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J BiolChem. 2003;278:13740-13746.
161. Bjørbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004;59:305-331.
162. MyersMGJr, Heymsfield SB, Haft C, et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 2012;15:150-156.
163. Lee Y, Naseem RH, Duplomb L, et al. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci U S A. 2004;101: 13624-13629.
164. Lee Y, Wang MY, Kakuma T, et al. Liporegulation in dietinduced obesity: the antisteatotic role of hyperleptinemia. J Biol Chem. 2001;276:5629-5635.
165. Oral EA, Burant C. Leptin and insulin resistance: good, bad, or still unclear? Am J Physiol Endocrinol Metab. 2009;296:E394-E395.
166. Paz-Filho G, Esposito K, Hurwitz B, et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am J Physiol Endocrinol Metab. 2008;295:E1401-E1408.
167. Unger RH. Hyperleptinemia protecting the heart from lipid overload. Hypertension. 2005;45:1031-1034.
168. Waelput W, Verhee A, Broekaert D, et al. Identification and expression analysis of leptin-regulated immediate early response and late target genes. Biochem J. 2000; 348(Pt 1):55-61.
169. Bjørbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell. 1998;1:619-625.
170. Dunn SL, Björnholm M, Bates SH, Chen Z, Seifert M, MyersMGJr. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr(1138) of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol. 2005;19:925-938.
171. Eyckerman S, Broekaert D, Verhee A, Vandekerckhove J, Tavernier J. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 2000;486:33-37.
172. Münzberg H, Flier JS, Bjørbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology. 2004;145:4880-4889.
173. BjörnholmM,Münzberg H, Leshan RL, et al. Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest. 2007;117:1354-1360.
174. Morrison CD, White CL, Wang Z, et al. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology. 2007;148:433-440.
175. Ren D, Li M, Duan C, Rui L. Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. Cell Metab. 2005;2:95-104.
176. Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, Kahn BB. Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem. 2008;283: 14230-14241.
177. Feng GS. Shp2 as a therapeutic target for leptin resistance and obesity. Expert Opin Ther Targets. 2006;10:135-142.
178. Zhang EE, Chapeau E, Hagihara K, Feng GS. Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc Natl Acad Sci U S A. 2004;101:16064-16069.
179. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides. 1996;17:305-311.
180. El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105:1827-1832.
181. Hileman SM, Pierroz DD, Masuzaki H, et al. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology. 2002;143:775-783.
182. Gertler A. Development of leptin antagonists and their potential use in experimental biology and medicine. Trends Endocrinol Metab. 2006;17:372-378.
183. Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9:35-51.
184. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457-461.
185. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135: 61-73.
186. Koch C, Augustine RA, Steger J, et al. Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic insulin sensitivity. J Neurosci. 2010;30: 16180-16187.
187. Chua SC Jr, Chung WK, Wu-Peng XS, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996;271:994-996.
188. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387:903-908.
189. Farooqi IS, Keogh JM, Kamath S, et al. Partial leptin deficiency and human adiposity. Nature. 2001;414:34-35.
190. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093-1103.
191. Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A. 2004;101:4531-4536.
192. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879-884.
193. Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89:4821-4826.
194. Paz-Filho G, Mastronardi C, Delibasi T, Wong ML, Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arq Bras Endocrinol Metab. 2010;54:690-697.
195. Fatima W, Shahid A, Imran M, et al. Leptin deficiency and leptin gene mutations in obese children from Pakistan. Int J Pediatr Obes. 2011;419-427.
196. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18:213-215.
197. Mantzoros CS, Ozata M, Negrao AB, et al. Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans. J Clin Endocrinol Metab. 2001;86:3284-3291.
198. Andreev VP, Paz-Filho G, Wong ML, Licinio J. Deconvolution of insulin secretion, insulin hepatic extraction posthepatic delivery rates and sensitivity during 24-hour standardized meals: time course of glucose homeostasis in leptin replacement treatment. Horm Metab Res. 2009;41: 142-151.
199. Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392:398-401.
200. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356:237-247.
201. Hunt CE, Lindsey JR, Walkley SU. Animal models of diabetes and obesity, including the PBB/Ld mouse. Fed Proc. 1976;35:1206-1217.
202. Haluzik M, Colombo C, Gavrilova O, et al. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology. 2004;145:3258-3264.
203. Mantzoros CS. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? Endocr Pract. 2010;29: 1-18.
204. Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7:137-150.
205. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta. 2009;1791: 507-513.
206. Reue K, Péterfy M. Mouse models of lipodystrophy. Curr Atheroscler Rep. 2000;2:390-396.
207. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-76.
208. Asilmaz E,CohenP, MiyazakiM,et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest. 2004;113:414-424.
209. Gavrilova O, Marcus-Samuels B, Leon LR, Vinson C, Reitman ML. Leptin and diabetes in lipoatrophic mice. Nature. 2000;403:850.
210. Ebihara K, Ogawa Y, Masuzaki H. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes. 2001; 50:1440-1448.
211. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16:310-323.
212. Vadacca M, Margiotta DP, Navarini L, Afeltra A. Leptin in immuno-rheumatological diseases. Cell Mol Immunol. 2011;8:203-212.
213. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy.NEngl J Med. 2002;346:570-578.
214. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-1350
215. Ebihara K, Masuzaki H, Nakao K. Long-term leptin-replacement therapy for lipoatrophic diabetes.NEngl JMed. 2004;351:615-616.
216. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54: 1994-2002.
217. Matarese G, Sanna V, Lechler RI, et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes. 2002;51:1356-1361.
218. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53:27-35.
219. Ebihara K, Kusakabe T, HirataM,et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92:532-541.
220. Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract. 2010;16:324-333.
221. Chan JL, Lutz K, Cochran E, et al. Clinical effects of longterm metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17:922-932.
222. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87:2395.
223. Simha V, Subramanyam L, Szczepaniak L, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97:785-792.
224. Leow MK, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88:1961-1976.
225. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40: 1837-1845.
226. Magkos F, Mantzoros CS. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metab Clin Exp. 2011;60:749-753.
227. Power R, Tate H, McGill S, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect. 2003;79:137-141.
228. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.NEngl J Med. 2005; 352:448-462.
229. Brennan AM, Lee JH, Tsiodras S, et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol. 2009;160:173-176.
230. Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly WG,Santiago JV, LandtM.Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metab Clin Exp. 1997;46:303-305.
231. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36:795-802.
232. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003;88:627-636.
233. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91:2605-2611.
234. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009;94:1137-1144.
235. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000; 284:472-477.
236. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140:786-794.
237. Sekhar RV, Jahoor F, Iyer D, et al. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism. 2012;61:1395-1403
238. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.
239. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010; 95:4291-4304.
240. Tong Q, Sankalé JL, Hadigan CM. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab. 2003;88:1559-1564.
241. Vigouroux C, Maachi M, Nguyên TH. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503-1511.
242. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr. 2002;31: 514-520.
243. Duntas LH, Popovic V, Panotopoulos G. Adiponectin: novelties in metabolism and hormonal regulation. Nutr Neurosci. 2004;7:195-200.
244. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946.
245. Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2×2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis. 2005;40:745-749.
246. Magkos F, Brennan A, Sweeney L, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metab Clin Exp. 2011;60:1045-1049.
247. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011;108:6585-6590.
248. Sienkiewicz E, Magkos F, Aronis KN, et al. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemicwomen. Metabolism. 2011;60:1211-1221.
249. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351:987-997.
250. Harris RB, Mitchell TD, Hebert S. Leptin-induced changes in body composition in high fat-fed mice. Exp Biol Med (Maywood). 2003;228:24-32.
251. Buettner R, Newgard CB, Rhodes CJ, O'Doherty RM. Correction of diet-induced hyperglycemia, hyperinsulinemia, and skeletal muscle insulin resistance by moderate hyperleptinemia. Am J Physiol Endocrinol Metab. 2000; 278:563-569.
252. Harris RB, Mitchell TD, Yan X, Simpson JS, RedmannSM Jr. Metabolic responses to leptin in obese db/db mice are strain dependent. Am J Physiol Regul Integr Comp Physiol. 2001;281:R115-R132.
253. Mantzoros CS, Frederich RC, Qu D, Lowell BB, Maratos-Flier E, Flier JS. Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin A mice despite suppression of hypothalamic neuropeptideYand circulating corticosterone concentrations. Diabetes. 1998;47:230-238.
254. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab. 2000;85: 4003-4009.
255. Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res. 2004;59:225-244.
256. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campfield LA, Saris WH. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord. 2002;26:504-509.
257. Zelissen PM, Stenlof K, Lean ME, et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebocontrolled trial. Diabetes Obes Metab. 2005;7:755-761.
258. Sumithran P, Prendergast LA, Delbridge E, et al. Longterm persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;1597-1604.
259. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115:3579-3586.
260. Ahima R, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996; 382:250-252.
261. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409-1421.
262. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab. 2002;87:2391-2394.
263. Aronis KN, Diakopoulos KN, Fiorenza CG, Chamberland JP, Mantzoros CS. Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans. Diabetologia. 2011;54: 2358-2367.
264. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008;105:7257-7262.
265. Kiess W, Anil M, Blum WF, et al. Serum leptin levels in children and adolescents with insulin-dependent diabetes mellitus in relation to metabolic control and body mass index. Eur J Endocrinol. 1998;138:501-509.
266. Havel PJ, Uriu-Hare JY, Liu T, et al. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol. 1998;274:1482-1491.
267. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes. 1999;48:1487-1492.
268. Chan JL, Mietus JE, Raciti PM, Goldberger AL, Mantzoros CS. Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clin Endocrinol (Oxf). 2007;66:49-57.
269. Lin CY, Higginbotham DA, Judd RL, White BD. Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab. 2002;282: 1084-1091.
270. Hidaka S, Yoshimatsu H, Kondou S, et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J. 2002;16:509-518.
271. German JP, Thaler JP, Wisse BE, et al. Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology. 2011;152:394-404.
272. Denroche HC, Levi J, Wideman RD, et al. Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling. Diabetes. 2011;60:1414-1423.
273. German JP, Wisse BE, Thaler JP, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes. 2010;59:1626-1634.
274. Naito M, Fujikura J, Ebihara K, et al. Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice. Diabetes. 2011;60: 2265-2273.
275. Saryusz-Wolska M, Szymanska-Garbacz E, Jablkowski M, et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch MedWewn. 2011;121:61-66.
276. Park JY, Chong AY, Cochran EK, et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab. 2008;93:26-31.
277. Oral EA. Leptin for type 1 diabetes: coming onto stage to be (or not?). Pediatr Diabetes. 2011;13:68-73.
278. Toyoshima Y, Gavrilova O, Yakar S, et al. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology. 2005;146:4024-4035.
279. Kusakabe T, Tanioka H, Ebihara K, et al. Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia. 2009;52: 675-683.
280. Banks WA. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. Curr Pharm Design. 2001;7:125-133.
281. Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes. 2011;60:1474-1477.
282. Trevaskis JL, Lei C, Koda JE, Weyer C, Parkes DG, Roth JD. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity. 2010;18:21-26.
283. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009;17:1736-1743.
284. Hwang JJ, Chan JL, Ntali G, Malkova D, Mantzoros CS. Leptin does not directly regulate the pancreatic hormones amylin and pancreatic polypeptide: interventional studies in humans. Diabetes Care. 2008;31:945-951.
285. Bates SH, Stearns WH, Dundon TA, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature. 2003;421:856-859.
286. Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, Schwartz MW. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab. 2005;2: 411-420.
287. Vernon G, Baranova A, Younossi Z. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
288. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649.
289. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957-969.
290. Ikejima K, Okumura K, Lang T, et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res. 2005;33:151-154.
291. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86:s858-s866.
292. Yan K, Deng X, Zhai X, et al. p38 mitogen-activated protein kinase and liver X receptor-α mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol Med. 2012;18:10.
293. Cao Q, Mak KM, Ren C, Lieber CS. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells. J Biol Chem. 2004;279:4292-4304.
294. Cao Q, Mak KM, Lieber CS. Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J Hepatol. 2007;46:124-133.
295. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology. 2008;48:2016-2026.
296. Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol. 2007;22:S87-S92.
297. Dalamaga M, Crotty BH, Fargnoli J, et al. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece. Cancer Causes Control. 2010;21:1451-1459.
298. Potter JJ, Womack L,Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys ResCommun. 1998;244:178-182.
299. Wang J, Leclercq I, Brymora JM, et al. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology. 2009;137:713-723.
300. Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012;16:44-54.
301. HuangXD,Fan Y,ZhangH, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. W J Gastroenterol. 2008;14:2888-2893.
302. Wong V, Hui AY, Tsang S, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:1154-1161.
303. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403-409.
304. Muñoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of mexican patients with nonalcoholic steatohepatitis. Ann Hepatol. 2009;8:123-128.
305. Argentou M, Tiniakos DG, Karanikolas M, et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19:1313-1323.
306. Chalasani N, Crabb DW, Cummings OW, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-2776.
307. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol. 2004; 41:943-949.
308. Nobili V, Manco M, Ciampalini P, et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol. 2006; 155:735-743.
309. Medici V, Ali MR, Seo S, et al. Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease. Obesity. 2012;18:2268-2273.
310. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969-974.
311. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012
312. Lutchman G, Promrat K, Kleiner DE, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol. 2006;4:1048-1052.
313. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711-1718.
314. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101-107.
315. Dohil R, Schmeltzer S, Cabrera B, et al. Enteric-coated cysteamine for the treatment of paediatric non[b]-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011; 33:1036-1044.
316. BalmerML,Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009;29:1184-1188.
317. Gonciarz M, Bielański W, Partyka R, et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. J Pineal Res. 2013;54:154-161.
318. Hoda MR, Hamza A, Fischer K, et al. [Obesity as a risk factor for prostate cancer: role for adipocytokines and involvement of tyrosine kinase pathway]. Aktuelle Urol. 2010;41:178-183.
319. Gogas H, Trakatelli M, Dessypris N, et al. Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study. Ann Oncol. 2008;19:384-389.
320. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, TanakaK. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol. 2010;119:65-69.
321. Grossmann ME, Cleary MP. The balance between leptin and adiponectin in the control of carcinogenesis-focus on mammary tumorigenesis. Biochimie. 2012;94:2164-2171.